Welcome to our dedicated page for Pasithea Therapeutics news (Ticker: KTTAW), a resource for investors and traders seeking the latest updates and insights on Pasithea Therapeutics stock.
Pasithea Therapeutics Corp. develops clinical-stage biotechnology programs centered on PAS-004, a next-generation macrocyclic MEK inhibitor. Company news for KTTAW, the Nasdaq-listed warrants to purchase Pasithea common stock, typically covers PAS-004 clinical and regulatory updates in neurofibromatosis type 1-associated plexiform neurofibromas, MAPK pathway-driven advanced solid tumors, ALS, and other disease areas tied to RASopathies and CNS disorders.
Recurring developments include FDA designations, clinical pharmacokinetic, pharmacodynamic, safety, and tolerability data, research grants, healthcare conference presentations, and capital actions such as public equity offerings. The coverage also reflects Pasithea's status as a public biotechnology issuer with common stock and warrants listed on The Nasdaq Capital Market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Pasithea Therapeutics Corp. (KTTA) announced that Prof. Lawrence Steinman will deliver a keynote address at the AAAS Annual Meeting on March 4, 2023. Prof. Steinman's research linking the Epstein-Barr virus to multiple sclerosis (MS) was recognized as a runner-up for the 2022 Science Magazine Breakthrough of the Year.
The company's PAS-002 program aims to develop a DNA plasmid vaccine targeting GlialCAM, a protein implicated in MS, providing potential treatment avenues for this chronic autoimmune disease affecting 2.8 million worldwide.
Pasithea Therapeutics Corp. announced that Lawrence Steinman, Chairman, will deliver a significant lecture at the ACTRIMS Forum in San Diego on February 23, 2023. The event, themed “MS: Going Viral,” focuses on the role of the Epstein-Barr virus in Multiple Sclerosis (MS), which relates to the Company's PAS-002 drug discovery program. PAS-002 aims to create an engineered DNA plasmid vaccine targeting GlialCAM, a protein implicated in MS. MS affects 2.8 million people globally, with relapsing remitting MS being the most common type. Steinman's research was recognized as a runner-up for Science Magazine’s 2022 Breakthrough of the Year.
Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced that its Chairman, Prof. Lawrence Steinman, will receive the 2023 Pioneer in Medicine Award for significant contributions to brain mapping and therapeutics at the 20th Annual Gathering for the Cure on February 17, 2023. This award is presented by the Society for Brain Mapping & Therapeutics (SBMT) and the World Brain Mapping Foundation, recognizing pioneering work in fields like multiple sclerosis (MS). The company is focusing on developing a proprietary engineered DNA plasmid vaccine, PAS-002, targeting GlialCAM for MS treatment, affecting over 2.3 million people worldwide.